Ozempic faces $2 billion lawsuits as patients report stomach paralysis, vision loss
A popular drug for ozmpic, diabetes and weight loss is now under heavy legal fire. The cases of more than $ 2 billion have been submitted, claiming that due to severe health problems of the drug, including gastric composition and vision loss. The drug developed by Novo Nordisk was originally approved for type -2 diabetes, but achieved rapid traction as an off -lab -lable solution for weight management. This increase in demand has also increased reports on harmful side effects such as gastroperis, intestinal obstruction and eye complications. Patients claim that no correct warnings were given, which increased the concerns of the safety of GLP-1 receptor medicines. Experts are now encouraging strict guidelines for monitoring and clear security. When cases are stacked, regulators can be forced to function, which can open how weight loss medicines are prescribed.
The Key points
- Patients claim that the drug caused gastric molding (gastroperis).
- Vision losses and complications of the eye are also reported to side effects.
- Originally approved for type -2 diabetes treatment of Novo Nordisk.
- The off-marked widely used for weight loss and increases demand.
- GLP -1 increases the concerns of long -term safety for medication.
- Regulatory bodies can tighten labeling and safety requirements.
- Doctors recommend close monitoring of patients using ozapika.
- Dispute doubts about weight -which experiences drug security.
Disclaimer: This preview includes title, image, and description automatically sourced from the original website (www.financialexpress.com) using publicly available metadata / OG tags. All rights, including copyright and content ownership, remain with the original publisher. If you are the content owner and wish to request removal, please contact us from your official email to no_reply@newspaperhunt.com.
